Lionheart Health, Inc.

Bioelectric protein expression | Regenerative aesthetics | Healthspan longevity

Core thesis. Lionheart is developing a platform that uses programmed bioelectric stimulation to influence the expression and release of proteins associated with regeneration, recovery and healthy aging. Its initial commercial focus combines regenerative aesthetics and healthspan longevity with clinic services, at-home devices and recurring memberships. Bioelectric-enhanced biologics extend the research strategy beyond device-only interventions.

Platform focus: signal, protein, biological response

The company's central hypothesis is that selected electrical signals can modulate specific biological pathways rather than deliver a single generic stimulation effect. Proteins of interest include **Klotho, follistatin and BDNF**, alongside other targets associated with tissue repair, muscle function and brain health. Protocol effects depend on signal parameters, tissue exposure, patient characteristics and treatment context; protein changes must be validated separately from clinical benefit.

Strategic pillar	Applications and commercial rationale
Regenerative aesthetics	HairCell and SkinStim programs combine bioelectric stimulation with selected light, electromagnetic, serum and PRF modalities. Clinic protocols and home continuity create multiple product and service opportunities.
Healthspan longevity	Klotho-Up integrates lifestyle, exercise, BodStim EMS, targeted stimulation and biomarker measurement. Muscle, brain and immune function are central outcomes of interest.
Bioelectric-enhanced biologics	Research explores stimulation alongside PRF, peptides and, in advanced investigational programs, cells, gene delivery and secretomes. The aim is to improve biological response; incremental benefit requires controlled testing.

One platform, multiple routes to market

Clinic: Lionheart 240 Stimulus supports a program-based device model. **At home:** the 240 Portable, Brain Band and BodStim support continuity between visits. **Recurring:** memberships, clinician services, software programs, product sales and clinic licensing offer complementary revenue streams. The investment case depends on converting this breadth into repeat purchases, clinic utilization and durable unit economics.

Financial snapshot: management-provided figures

2024 revenue	2025 revenue	2026 sales forecast
$77,000	$353,000	$500,000

The revised 2026 forecast implies approximately 42% growth over 2025. These figures are company supplied and have not been independently verified here; the 2026 figure is a forecast, not reported revenue.

Experienced leadership across science and commercialization

Leadership: Howard J. Leonhardt, Executive Chairman & Co-CEO; Scott Hoots, Co-CEO; Scott Jordan, CFO; Dr. Leslie Miller, CMO; Brian Lasater, CTO; Dr. Jorge Genovese, VP Bioelectric Research; Kelsie Leonhardt, Chief NeuroScientist, Manager Research Clinics.

Lionheart Health, Inc.

Execution priorities | Evidence development | Catalysts and investment considerations

Bioelectric-enhanced biologics: the expansion opportunity

Lionheart's longer-term ambition is a shared technology foundation for addressing a broad range of age-related functional decline and ailments. The strategy combines **bioelectric control of protein expression** with biological payloads or adjunct therapies, seeking to coordinate tissue signaling, repair and recovery. This is a platform development objective, not evidence that the company can treat every aging-related disease.

Near-term combinations include bioelectric-enhanced PRF and peptides within aesthetics and recovery research. Advanced concepts such as **KlothoPatch II and the Lionheart Octopus** explore delivery and stimulation across organs. Cell- and gene-based approaches, implanted systems and new disease indications require their own safety, efficacy and regulatory development pathways.

Evidence: focus on incremental clinical value

Management reports pilot and observational experience across brain, muscle, hair, skin, joint and vision programs. These signals support further research, but outcomes from multi-modal protocols cannot be attributed to stimulation alone without appropriate controls. Protein-expression findings, biomarker changes and patient outcomes are distinct evidence layers.

Priority study design: compare stimulation plus biologic against the same biologic alone; define signal parameters and dose; prespecify meaningful clinical endpoints; track adverse events and durability; and standardize laboratory assays. For healthspan, functional muscle, cognitive and immune outcomes should accompany Klotho and other exploratory biomarkers.

Milestones that would strengthen the investment case

Workstream	Decision-relevant milestone
Commercial execution	Demonstrate repeatable clinic onboarding, device sell-through, membership retention and program utilization.
Clinical development	Produce controlled combination studies and reproducible protein-expression results linked to clinically meaningful outcomes.
Regulatory readiness	Document each product's intended use, applicable clearance and investigational status; pursue authorization for new indications where required.
Financial and capital readiness	Complete financial reporting and audit work; fund development and commercialization; advance the contemplated Nasdaq Capital Market direct listing, subject to SEC review and exchange requirements.

Principal investment considerations

Opportunity: a reusable device-and-program architecture could support several markets and recurring revenue. **Risks:** limited-scale commercial execution, funding needs, early-stage clinical evidence, uncertain incremental benefit from combinations, and separate regulatory requirements across products and indications. Platform breadth may increase both market opportunity and development cost.

Basis and disclosure: Prepared from the company-supplied investor materials and October 9, 2026 forecast revision. Product-specific cleared uses do not establish approval of protein-expression claims, aesthetics or longevity outcomes, or investigational biologic combinations. This company-prepared brief is not issued by or affiliated with Piper Sandler or H.C. Wainwright and is not an independent research recommendation. Forward-looking objectives and forecasts are subject to execution, clinical, regulatory and financing uncertainty.